CDC Admits No Data Support Advice To Take Mpox, Influenza, And COVID Shots Together
ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero
Source: zerohedge.com
Page 48 - Peter Marks News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Peter Marks. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Peter Marks Today - Breaking & Trending Today
FDA Approves First Cell-Based Therapies For Treatment Of Sickle Cell Disease - Life Sciences, Biotechnology & Nanotechnology
On December 8, 2023, the FDA approved the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older—Vertex's CASGEVY and Bluebird's LYFGENIA.
Source: mondaq.com
2023 was a big year for CRISPR-based gene editing but challenges remain
2023 was an important year for patients with sickle cell disease. The FDA approved Vertex’s “Casgevy,” a CRISPR-based therapy for the treatment of sickle cell disease marking it as the first genetically edited therapy to reach the general market.
Source: yahoo.com
2023 was a big year for CRISPR-based gene editing but challenges remain
2023 was an important year for patients with sickle cell disease. The FDA approved Vertex’s “Casgevy,” a CRISPR-based therapy for the treatment of sickle cell disease marking it as the first genetically edited therapy to reach the general market.
Source: engadget.com
2023 was a big year for CRISPR-based gene editing but challenges remain
2023 was an important year for patients with sickle cell disease. The FDA approved Vertex’s “Casgevy,” a CRISPR-based therapy for the treatment of sickle cell disease marking it as the first genetically edited therapy to reach the general market.
Source: yahoo.com